🧬 New Technology added at Pharmidex in house now: Enhancing Precision in Coagulation Testing🧬
June 9, 2025

We're excited to announce the integration of the Sysmex CA-660 semi-automated Coagulation Analyzer into our lab infrastructure.


This compact yet powerful instrument brings clinical-grade coagulation testing to our preclinical workflows, enabling:


✅ High-precision clotting, chromogenic & immunoassays

✅ Low sample & reagent volume needs ideal for preclinical models

✅ Robust data reproducibility for decision-critical insights

✅ Easy-to-use interface for rapid turnaround


With the CA-660, Pharmidex is further enhancing its capacity to deliver accurate, consistent and fast coagulation studies, a key component in safety pharmacology, clinical pathology and drug development.


This system supports our mission to provide high-quality bioanalytical, DMPK and toxicology services to our partners in biotech and pharma.

Sysmex CA-660 semi-automated Coagulation Analyzer

#Pharmidex #Sysmex #CoagulationTesting #DrugDevelopment #PreclinicalResearch #Bioanalysis #DMPK #LifeSciences #InnovationInBiotech

June 3, 2025
This initiative provides a fantastic opportunity to learn directly from key voices across the MSCA community, including insights from a project coordinator, beneficiary, and third-country partner, all sharing valuable lessons and best practices. We are proud to announce that our Managing Director, Professor Mo Alavijeh ( Pharmidex , University of Hertfordshire ), will participate in the Round Table Discussion on “MSCA Staff Exchanges: Challenges and Opportunities”, including an interactive Q&A session. Mo will be attending in person at the Universitat d'Alacan t and is looking forward to engaging with attendees, building new connections, and exploring collaborative opportunities, particularly with those interested in working alongside a UK-based SME deeply committed to international research excellence. Monika Holik , Begoña Arano , Sotirios Kiokias , Rodrigo Gutierrez Dominguez , Xavier Eekhout Chicharro , Joaquin Silvestre , Izaskun Lacunza , Julio Marchamalo Amado , Mónika Holik
June 2, 2025
We’re excited to announce that Pharmidex will be exhibiting at the BMCS 5th Synthesis in Drug Discovery and Development Conference, taking place from Tuesday 3rd to Wednesday 4th June 2025 🔗 https://lnkd.in/e_GJM8S7 Our Business Development Manager, J anette Dalay Robertson , will be attending and is looking forward to engaging with fellow professionals to foster collaborations and explore how Pharmidex can support your drug discovery and development journey. Whether you're looking for expertise in in silico, ADME, DMPK, bioanalysis, or neuroscience models, stop by our booth and let’s connect! 💬 Don’t miss the chance to meet Janette Dalay Robertson and discover how Pharmidex promotes scientific excellence through flexible, high-quality preclinical research partnerships.
May 28, 2025
At Pharmidex , we stand in solidarity with all patients, families, and healthcare professionals impacted by blood cancers. This day is a powerful reminder of the urgent need for continued innovation, collaboration, and compassion in the fight against these life-threatening diseases. Through our cutting-edge preclinical services, including: PK/ADME studies CNS penetration & efficacy models in vivo/in vitro pharmacology bioanalytical and regulatory support  we contribute to the development of safer, more effective therapies for blood cancers. 🧬 We’re proud to collaborate with leading biopharma companies, academic institutions, and charities to accelerate the discovery and delivery of new treatments. ❤️ Today, we renew our commitment to this mission working towards a future where every patient has access to a cure. 🔗 Learn more and support the cause: https://www.dkms.org.uk
More Posts